Quarterly ResultMay 20, 2026, 04:11 PM
Vivos Therapeutics Q1 Revenue +70% to $5.1M; Net Loss Doubles to $7.8M
AI Summary
Vivos Therapeutics reported a 70% year-over-year revenue increase to $5.1 million for the first quarter ended March 31, 2026, largely driven by the acquisition of The Sleep Center of Nevada Management (SCN) and its business model pivot. Gross profit more than doubled to $3.1 million, with gross margin improving to 60%. However, the company's net loss also doubled to $7.8 million, primarily due to increased operating expenses related to business expansion and one-time costs. Vivos is actively working on integrating SCN, increasing productivity, securing new funding, and restructuring debt to improve stockholders' equity and reduce cash burn.
Key Highlights
- Total revenue increased 70% to $5.1 million for Q1 2026, up from $3.0 million in Q1 2025.
- Service revenue grew to $3.7 million in Q1 2026 from $1.2 million in Q1 2025.
- Gross profit increased 103% to $3.1 million in Q1 2026, with gross margin rising to 60%.
- Operating expenses increased 78% to $9.7 million in Q1 2026, compared to $5.4 million in Q1 2025.
- Net loss increased 100% to $7.8 million in Q1 2026, from $3.9 million in Q1 2025.
- Cash and cash equivalents were $2.1 million at March 31, 2026.
- Stockholders' equity was a deficit of $1.1 million at March 31, 2026.
- Oral appliance sales volume rose 42% to 5,304 units in Q1 2026.
Price Impact
More from VVOS